HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329.

Abstract
Expression of the EP4 receptor, a prostaglandin (PG)E2 receptor subtype, as well as disease suppression by the administration of a selective EP4 agonist (ONO-AE1-329) was investigated in the colorectal mucosa of rats with dextran sodium sulphate (DSS)-induced colitis. Rats were given drinking water containing 3% DSS for 2 weeks. Expression of EP4 receptor mRNA was barely detectable under normal conditions according to reverse transcription-polymerase chain reaction (RT-PCR). By 1 week after the initial administration of DSS, the receptor mRNA was strongly expressed. After ONO-AE1-329 was administered intracolonically to rats with DSS colitis for 7 consecutive days, erosion and ulceration decreased. Peripheral white blood cell (WBC) counts became less elevated. Interleukin (IL)-1beta and growth-regulated gene product/cytokine-induced neutrophil chemoattractant (GRO/CINC-1) concentrations in colorectal mucosa were lower than in colitis control group (IL-1beta: 12.8 +/- 4.6 and 30.8 +/- 6.2 microg/mg protein, P < 0.05; GRO/CINC-1: 15.5 +/- 3.0 and 39.2 +/- 5.4 microg/mg protein, P < 0.05), and the expression of the corresponding cytokine mRNA was strongly suppressed. IL-10 concentration was higher than in control group (14.5 +/- 1.7 and 7.9 +/- 1.2 microg/mg, P < 0.05), and the mRNA was more strongly expressed. These results suggest that the EP4 receptor is important in colonic inflammation, and that PGE2 suppresses DSS colitis at least partly via the EP4 receptor and the above cytokine changes. Intracolonic administration of selective EP4 agonist might have therapeutic applicability in inflammatory bowel disease such as ulcerative colitis.
AuthorsM Nitta, I Hirata, K Toshina, M Murano, K Maemura, N Hamamoto, S Sasaki, H Yamauchi, K Katsu
JournalScandinavian journal of immunology (Scand J Immunol) Vol. 56 Issue 1 Pg. 66-75 (Jul 2002) ISSN: 0300-9475 [Print] England
PMID12100473 (Publication Type: Journal Article)
Chemical References
  • Anti-Ulcer Agents
  • Chemokine CXCL1
  • Chemokines, CXC
  • Chemotactic Factors
  • Cxcl1 protein, rat
  • Growth Substances
  • Intercellular Signaling Peptides and Proteins
  • Interleukin-1
  • Methyl Ethers
  • ONO-AE1-329
  • Ptger2 protein, rat
  • Ptger4 protein, rat
  • RNA, Messenger
  • Receptors, Prostaglandin E
  • Receptors, Prostaglandin E, EP2 Subtype
  • Receptors, Prostaglandin E, EP4 Subtype
  • Interleukin-10
  • Dextran Sulfate
  • Peroxidase
  • Dinoprostone
Topics
  • Acute Disease
  • Animals
  • Anti-Ulcer Agents (administration & dosage, pharmacology)
  • CHO Cells
  • Chemokine CXCL1
  • Chemokines, CXC
  • Chemotactic Factors (biosynthesis, genetics, immunology)
  • Colitis (chemically induced, genetics, immunology, pathology)
  • Colon (enzymology, immunology, pathology)
  • Cricetinae
  • Dextran Sulfate (adverse effects)
  • Dinoprostone (metabolism)
  • Dose-Response Relationship, Drug
  • Gene Expression
  • Growth Substances (biosynthesis, genetics, immunology)
  • Intercellular Signaling Peptides and Proteins
  • Interleukin-1 (biosynthesis, genetics, immunology)
  • Interleukin-10 (biosynthesis, genetics, immunology)
  • Leukocyte Count
  • Male
  • Methyl Ethers (administration & dosage, pharmacology)
  • Peroxidase (metabolism)
  • RNA, Messenger
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Prostaglandin E (agonists, genetics)
  • Receptors, Prostaglandin E, EP2 Subtype
  • Receptors, Prostaglandin E, EP4 Subtype
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: